1. Home
  2. QXL vs CRDF Comparison

QXL vs CRDF Comparison

Compare QXL & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum X Labs Inc. Common Stock

QXL

Quantum X Labs Inc. Common Stock

N/A

Current Price

$5.03

Market Cap

75.6M

Sector

Technology

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$0.92

Market Cap

86.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QXL
CRDF
Founded
N/A
1999
Country
Israel
United States
Employees
21
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.6M
86.8M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
QXL
CRDF
Price
$5.03
$0.92
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
77.7K
1.6M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.37
EPS
N/A
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
49.61
52 Week Low
$4.05
$0.76
52 Week High
$7.70
$3.31

Technical Indicators

Market Signals
Indicator
QXL
CRDF
Relative Strength Index (RSI) N/A 41.26
Support Level N/A N/A
Resistance Level N/A $1.66
Average True Range (ATR) 0.00 0.05
MACD 0.00 0.02
Stochastic Oscillator 0.00 92.72

Price Performance

Historical Comparison
QXL
CRDF

About QXL Quantum X Labs Inc. Common Stock

Quantum X Labs Inc is an Israel-based multi-disciplinary quantum technology company focused on the research, development, and commercialization of quantum technologies and intellectual property. The company operates across a broad range of domains, including quantum computing, quantum sensing, navigation systems, atomic clocks, and quantum algorithms, with applications spanning defense, aerospace, transportation, cybersecurity, and life sciences.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: